Felix Hilpert - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Felix Hilpert

Showing results (41-50 of 107) with videos related to

Pageof 11

Sort By:

ACS Applied Materials & Interfaces|April 5, 2023

Mechanistic Insight into Solution-Based Atomic Layer Deposition of CuSCN Provided by In Situ and Ex Situ MethodsFelix Hilpert, Pei-Chun Liao, Evanie Franz, et al.

Genes, Chromosomes & Cancer|January 31, 2013

Breakpoint characterization of the der(19)t(11;19)(q13;p13) in the ovarian cancer cell line SKOV-3Wiebke Onkes, Regina Fredrik, Francesca Micci, et al.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 31, 2023

Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study GroupPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 6, 2025

Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observationsPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 18, 2019

TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)Alexander Reuss, Andreas du Bois, Philipp Harter, et al.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)Philipp Harter, David Gershenson, Catherine Lhomme, et al.

Gynecologic Oncology|January 6, 2016

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)Günter Emons, Christian Kurzeder, Barbara Schmalfeldt, et al.

European Journal of Cancer (Oxford, England : 1990)|July 7, 2019

Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapyChee Khoon Lee, Rebecca Asher, Michael Friedlander, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancerMartin R Stockler, Felix Hilpert, Michael Friedlander, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialEric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, et al.

Pageof 11

Search research articles

Showing results (41-50 of 107) with videos related to

Sort By:

Pageof 11

ACS Applied Materials & Interfaces|April 5, 2023

Mechanistic Insight into Solution-Based Atomic Layer Deposition of CuSCN Provided by In Situ and Ex Situ MethodsFelix Hilpert, Pei-Chun Liao, Evanie Franz, et al.

Genes, Chromosomes & Cancer|January 31, 2013

Breakpoint characterization of the der(19)t(11;19)(q13;p13) in the ovarian cancer cell line SKOV-3Wiebke Onkes, Regina Fredrik, Francesca Micci, et al.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 31, 2023

Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study GroupPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 6, 2025

Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observationsPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 18, 2019

TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)Alexander Reuss, Andreas du Bois, Philipp Harter, et al.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)Philipp Harter, David Gershenson, Catherine Lhomme, et al.

Gynecologic Oncology|January 6, 2016

European Journal of Cancer (Oxford, England : 1990)|July 7, 2019

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialEric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, et al.

Pageof 11